2020
Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission
Pigeault R, Isaïa J, Yerbanga R, Dabiré K, Ouédraogo J, Cohuet A, Lefèvre T, Christe P. Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission. Scientific Reports 2020, 10: 10183. PMID: 32576924, PMCID: PMC7311528, DOI: 10.1038/s41598-020-67180-6.Peer-Reviewed Original ResearchConceptsGametocyte densityMosquito infection ratesBlood samplesInfection rateNew malaria control strategiesMajor global causeMalaria control strategiesLow parasite burdenGametocyte burdenGametocyte carriersParasite transmissionPlasmodium infectionMosquito transmission potentialRight extremitiesTransmissible stagesParasite burdenMosquito transmissionMalaria parasitesPlasmodium sppGlobal causeTransmission potentialGametocytesVector-borne diseasesDiseaseExtremities
2015
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilitiesAntibiotics in ingested human blood affect the mosquito microbiota and capacity to transmit malaria
Gendrin M, Rodgers F, Yerbanga R, Ouédraogo J, Basáñez M, Cohuet A, Christophides G. Antibiotics in ingested human blood affect the mosquito microbiota and capacity to transmit malaria. Nature Communications 2015, 6: 5921. PMID: 25562286, PMCID: PMC4338536, DOI: 10.1038/ncomms6921.Peer-Reviewed Original ResearchConceptsMass drug administration programsHigh antibiotic usageDrug administration programsBlood of childrenAnopheles gambiae mosquitoesMalaria infectionAntibiotic exposureMosquito bitesHigh riskAntibiotic usageMalaria reductionGut microbiotaMalaria transmissionCommunicable diseasesPlasmodium falciparumBloodIngested bloodGambiae mosquitoesAntibioticsHuman bloodDisease transmissionDiseaseMosquito survivalMosquito microbiotaVectorial capacity
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150